Nxera Pharma's partner Tempero Bio initiates Phase 2 trial for potential alcohol use disorder treatment

From GlobeNewswire: 2025-03-24 20:05:00

Nxera Pharma Co., Ltd. announces the initiation of a Phase 2 trial for TMP-301, a potential treatment for alcohol use disorder. The trial will also include a second Phase 2 trial for cocaine use disorder. Tempero Bio, Inc., Nxera’s partner, closed a $70 million financing for these trials and future developments. TMP-301 is a selective mGluR5 negative allosteric modulator. The Phase 2 study will evaluate the safety and effectiveness of TMP-301 compared to a placebo in patients with alcohol use disorder.

Nxera Pharma is a biopharma company focused on developing specialty medicines to address unmet medical needs globally. The company has over 30 active programs in its pipeline, including treatments for neurology, GI, immunology, metabolic disorders, and rare diseases. Nxera leverages its NxWave™ platform for drug discovery. Tempero Bio, a company created in 2020 to advance the clinical development of mGluR5 NAMs, acquired global rights to Nxera’s portfolio of candidates. No milestone payment is due for the Phase 2 trial initiation.

Forward-looking statements in the press release caution investors about potential risks in the development, patent protection, and commercialization of products. Adverse results in clinical trials, regulatory approval delays, and competition from other companies are among the risks highlighted. Nxera Pharma Group is committed to updating or revising any forward-looking statements as needed.



Read more at GlobeNewswire: Nxera Pharma’s Partner Tempero Bio Initiates Phase 2 Trial